江苏康为世纪生物科技股份有限公司 关于终止实施2024年限制性股票激励计划的公告

Group 1 - The company has decided to terminate the 2024 Restricted Stock Incentive Plan due to significant changes in the macroeconomic environment and market conditions since its introduction, which rendered the performance assessment indicators ineffective [7][61] - The board of directors approved the termination on January 9, 2026, and the decision will be submitted for shareholder approval [5][10] - The plan's termination includes the cancellation of 1,590,600 shares that were granted but not vested, along with the associated documents [5][7][61] Group 2 - The company will continue to optimize its compensation system and internal performance evaluation mechanisms to ensure effective employee motivation and support long-term development [8][61] - The termination of the incentive plan is in compliance with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [9][13] - The company will handle the related share payment expenses according to accounting standards, with the final impact on net profit to be determined by an audit report [9][10] Group 3 - The company has also approved the continued use of temporarily idle raised funds for cash management, with a maximum amount of up to RMB 150 million [16][18] - The funds will be used for purchasing safe, liquid, and principal-protected financial products, ensuring that the investment does not affect the normal operation of the fundraising projects [20][21] - The decision to manage idle funds was made to enhance the efficiency of fund usage and increase returns for shareholders [28][30]